693245-83-9Relevant academic research and scientific papers
Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human
Chen, Jiehao,Efanov, Alexander M.,Fang, Xiankang,Jiang, Yi,Jun Zhang, Xue,Li, Lei,Lin, Hua V.,Liu, Jia,Liu, Lian Zhu,Long Hu, Zhi,Ma, Tianwei,Thomas, Melissa K,Wang, Fan,Wang, Jingru,Xiao, Fei,Xu, Jianfeng,Zeng, Mi,Zhang, Lei,Zhen Zhang, Hai,Zhou, Jingye,Zou, Haixia,Zou, Zack
, (2020/01/28)
The discovery and optimization of a novel series of GPR142 agonists are described. These led to the identification of compound 21 (LY3325656), which demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. Compound 21 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.
Tetrahydropyranyl Benzamide Derivatives
-
Paragraph 0055-0056, (2018/07/31)
The present invention provides compounds of the Formula below wherein R, R1-R3 are as described herein; methods of treating patients for diabetes using the compounds, and processes for preparing the compounds
